Dr. Mikhail Blagosklonny is a world’s prominent oncologist and a researcher. He is experienced in cancer research on Impactjournals.com and works as a professor at the New York-based Roswell Park Cancer Institute. His brilliant works are recognized within and outside the United States.
Academics and professional expertise
Dr. Blagosklonny became a senior researcher and tutor at Roswell Park Cancer Institute New York in 2009. His appointment came after the Institute reviewed his extensive work experience gained from working with both colleges and other research institutes. He has an M.D in internal medicine and Ph.D. in cardiology and experimental medicine.
Upon completion of his higher studies, Dr. Blagosklonny was called upon to serve as an associate professor at New York Medical College. He taught all medical students at the college. In 2002, he was appointed as the senior scientist at Ordway Research Institute headquartered in Albany, New York. This position allowed Dr. Blagosklonny to focus on his life extension research on impactjournals.com.
Dr. Blagosklonny’s interests and research hypothesis
Dr. Blagosklonny research interests are remarkable; they include cancer, aging, targeted cancer therapies that protect normal cells from cancerous ones, and anti-aging drugs. He has made big strides in research world by formulating a hypothesis in the significance of TOR Signaling in aging and cancer. Dr. Mikhail Blagosklonny proposed that Rapamycin, a popular cancer drug, might be used to extend life. He has held this concept for years, and he hopes to prove it in the future.
Dr. Blagosklonny is the founder and chief editor of Oncotarget. Oncotarget is a peer-reviewed medical journal covering all areas of aging and oncology. Dr. Blagosklonny co-founded Oncotarget together with Andrei Gudkov in 2010. This journal is the leading open-access oncology journal in the United States. Additionally, he edits other journals such as Cancer Biology & Therapy. Dr. Blagosklonny also serves on the editorial board of Cell Death & Differentiation. He has authored over 270 papers with over 250,000 citations.